Postes actifs de Heiko von der Leyen
Sociétés | Poste | Début | Fin |
---|---|---|---|
ORGENESIS INC. | Chief Tech/Sci/R&D Officer | 01/09/2020 | - |
Historique de carrière de Heiko von der Leyen
Anciens postes connus de Heiko von der Leyen
Sociétés | Poste | Début | Fin |
---|---|---|---|
Hannover Clinical Trial Center GmbH | Corporate Officer/Principal | 01/01/2005 | 01/01/2017 |
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Chief Tech/Sci/R&D Officer | 01/01/2003 | 01/01/2004 |
Artiss GmbH | Chief Tech/Sci/R&D Officer | 01/01/2001 | 01/01/2002 |
Cardion GmbH
Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Chief Tech/Sci/R&D Officer | 01/01/1998 | 01/01/2001 |
Statistiques
Internationale
Allemagne | 5 |
Etats-Unis | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 4 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
ORGENESIS INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Cardion GmbH
Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Health Technology |
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Health Technology |
Hannover Clinical Trial Center GmbH | |
Artiss GmbH |
- Bourse
- Insiders
- Heiko von der Leyen
- Expérience